NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Clinical safety rating: safe
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Neomycin is minimally metabolized; excreted primarily unchanged in urine. Dexamethasone is metabolized in the liver via CYP3A4. |
| Excretion | Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible. |
| Half-life | Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed). |
| Protein binding | Neomycin: minimal to none (~0%). Dexamethasone: ~77% (primarily albumin). |
| Volume of Distribution | Neomycin: 0.2-0.4 L/kg (largely extracellular; limited to local sites). Dexamethasone: 0.6-1.0 L/kg (widely distributed; crosses blood-eye barrier). |
| Bioavailability | Ophthalmic (topical): minimal systemic absorption (<0.1% of dose for both drugs). |
| Onset of Action | Ophthalmic: neomycin/dexamethasone – within 24-48 h for infection/inflammation control; topical (eye drops) – minutes to hours for symptomatic relief. |
| Duration of Action | Ophthalmic: 4-6 h dosing interval typical; duration of clinical effect 6-12 h after single dose. Anti-inflammatory effect lasts 24-48 h after dexamethasone penetration. |
| Molecular Weight | Neomycin sulfate: 908.9 Da (neomycin B base: 614.6 Da; neomycin C base: 614.6 Da; as sulfate: 908.9 Da). Dexamethasone sodium phosphate: 516.41 Da (dexamethasone base: 392.46 Da). |
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for topical/ophthalmic/otic use; systemic absorption is negligible. For rare systemic use: avoid if eGFR <30 mL/min/1.73 m² due to cumulative ototoxicity and nephrotoxicity of neomycin. |
| Liver impairment | No dose adjustment required for topical/ophthalmic/otic use. For systemic use: caution in severe hepatic impairment (Child-Pugh C) due to potential corticosteroid toxicity; use lowest effective dose and shortest duration. |
| Pediatric use | Safety and efficacy in children have not been established for ophthalmic/otic use; use only if clearly needed. For topical: apply thin layer 1-3 times daily; avoid prolonged use. Weight-based dosing not applicable for topical/ophthalmic/otic routes. |
| Geriatric use | No specific dose adjustment required; use with caution due to increased risk of ocular adverse effects (e.g., increased intraocular pressure, cataract formation) with prolonged dexamethasone use. Monitor intraocular pressure and for secondary infections. |
| 1st trimester | Neomycin and dexamethasone are poorly absorbed after topical application, but systemic absorption may occur if applied to broken skin or large areas. Neomycin is an aminoglycoside with potential ototoxicity and nephrotoxicity, though minimal systemic exposure from this combination product is expected. Dexamethasone is a corticosteroid; first-trimester use is generally avoided unless benefit outweighs risk, as corticosteroids are associated with a small increased risk of oral clefts. However, the low systemic absorption from this formulation likely limits risk. |
| 2nd trimester | Use with caution; avoid prolonged use on large areas or broken skin. Animal studies with aminoglycosides have not shown teratogenicity, but there is no well-controlled human data. Dexamethasone has been associated with fetal growth restriction with chronic high-dose use, but this is unlikely with topical use. |
| 3rd trimester | Use with caution near term; corticosteroids can cause neonatal adrenal suppression if significant systemic absorption occurs. Prolonged use of topical corticosteroids in pregnancy has been associated with low birth weight, but the risk from this combination is minimal with appropriate use. |
Clinical note
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
| FDA category |
■ FDA Black Box Warning
Neomycin may cause neurotoxicity, ototoxicity, and nephrotoxicity, especially in patients with renal impairment or prolonged use. Avoid use in patients with myasthenia gravis or neuromuscular disorders.
| Common Effects | topical infections |
| Serious Effects |
Hypersensitivity to neomycin, dexamethasone, or any component of the formulationPerforated tympanic membrane (for otic preparations)Fungal, viral (e.g., herpes simplex, vaccinia, varicella), or tuberculous infections of the eye or earUntreated bacterial infectionsOcular herpes simplex
| Precautions | Prolonged use may lead to secondary infections (e.g., fungal), elevated intraocular pressure, cataract formation, delayed wound healing. Use caution in patients with glaucoma, diabetes, or tuberculosis. Discontinue if hypersensitivity, ototoxicity, or nephrotoxicity occurs. |
| Food/Dietary |
Loading safety data…
| Animal |
| Placental transfer | Both neomycin and dexamethasone can cross the placenta, but the degree is low after topical application due to poor systemic absorption. Dexamethasone is known to cross the placenta and reach fetal circulation, with approximately 50% of maternal serum levels. Neomycin crosses the placenta to a minimal extent. |
| Breastfeeding | Both neomycin and dexamethasone are poorly absorbed after topical application, and significant milk excretion is unlikely. However, neomycin may be transferred into breast milk if applied to large areas or broken skin, potentially affecting neonatal gut flora or causing ototoxicity, though this is theoretical. Dexamethasone is excreted in small amounts. The combination product is considered safe if used on limited areas for short durations; avoid application to breast or nipple area. |
| Lactation Rating | L2: Safer |
| Teratogenic Risk | Neomycin: Oral neomycin is poorly absorbed; topical/otic use results in negligible systemic absorption, thus minimal teratogenic risk. Dexamethasone: Corticosteroids are associated with a small increased risk of oral clefts when used in the first trimester (odds ratio ~1.3-1.6); second/third trimester use may cause fetal adrenal suppression, low birth weight, and preterm delivery. Overall risk is low with otic/ophthalmic doses. |
| Fetal Monitoring | No specific monitoring required for topical/otic use. With prolonged systemic corticosteroid use (high-dose, chronic), monitor for maternal hyperglycemia, fetal growth restriction via serial ultrasound, and neonatal adrenal insufficiency at birth. |
| Fertility Effects | No known effects on fertility from topical/otic neomycin or dexamethasone. Systemic high-dose corticosteroids may suppress gonadotropins and impair ovulation/ menstrual cyclicity. |
| No clinically significant food interactions for ophthalmic use. Systemic absorption is minimal, so no dietary restrictions are required. |
| Clinical Pearls | Neomycin sulfate ototoxicity risk is highest in patients with renal impairment; avoid prolonged use. Dexamethasone sodium phosphate may cause elevated intraocular pressure; monitor in glaucoma patients. This combination is typically used for short-term treatment of ophthalmic infections to limit neomycin sensitization and cataract risk. |
| Patient Advice | Do not use this medication longer than prescribed to reduce risk of eye damage or hearing loss. · Do not share this medication with others to prevent infection spread. · Apply eye drops with clean hands; avoid touching the dropper tip to any surface or the eye. · Temporary blurred vision may occur after application; avoid driving until vision clears. · Report any signs of allergy (rash, itching, swelling) or hearing changes immediately. |